Therapeutic Cures Through CRISPR-Based Precision Editing
Enhanced genome editing with an expanded CRISPR toolkit: Our CRISPR-Cas systems provide unprecedented power to edit the genome.
Our novel Cas nucleases enable genome editing results that might not be possible with other Cas nucleases.
Newly discovered CRISPR-Cas systems are strong candidates for genome editing due to their small size and unique PAM (protospacer adjacent motif) requirements. Using our protein discovery workflow, we have and continue to identify variants with flexibility to cut single or double-stranded DNA or RNA or to be used with novel DNA or RNA modifying modalities.
- Immuno-Oncology
- Autoimmune Diseases
- Liver Diseases
- Hematology
- Ophthalmology
- Neurology
- Neuromuscular Diseases
- Cardiovascular
Expanded Targeting
Edit more of the genome
With alternative and shorter PAM requirements, newly discovered nucleases can direct edits to an expanded set of DNA sequences.
Flexible Delivery
Expand delivery options
The small sizes of our Cas14 and CasΦ nucleases overcome the limitations to viral and non-viral delivery methods experienced with Cas9.
Higher Fidelity
Reduce off-target effects
Our nucleases can bind to DNA and RNA targets with high fidelity. They perform edits more accurately in the correct places.